In compliance with ASX Continuous Disclosure Rules, Genetic Technologies Ltd. has executed a Settlement and License Agreement with AutoImmun Diagnostika GmbH (AID) of Strassberg, Germany.

Under the terms of the Agreement, AID is granted non-exclusive rights to a number of GTG patents relating to its non-coding DNA technology. As with other similar agreements, the precise commercial terms of the Agreement are covered by formal confidentiality provisions and cannot be disclosed.

AID was not a counterparty to either of the two current patent infringement suits GTG has on file in the United States. Discussions between Genetic Technologies and AID regarding AID's use of the GTG non-coding technology have resulted in non-exclusive access to the technology for AID products and services as well as normalization of historical sales.

Discussions with other such parties are ongoing and progressing. Further details will be released to the Market as appropriate.

-Richard Park